Neurona Therapeutics is a clinical-stage biotherapeutics company developing regenerative cell therapies that permanently integrate into neural circuits, replace affected cells, and rebalance dysregulated electrical activity to repair the nervous system.

Neurona Therapeutics

Neurona is a biotherapeutics company developing neural cell therapies with single-dose curative potential for the treatment of chronic neurological disorders. Based on a novel neural cell lineage pioneered by the company’s scientific founders, Neurona has built a robust regenerative platform and is developing neuronal, glial, and gene-edited cell therapy candidates that provide long-term repair of dysfunctional neural networks for multiple neurological disorders. For more information about Neurona visit our website.

South Carolina Research Authority

National Institutes of Health

California Institute for Regenerative Medicine

California Institute of Regenerative Medicine (CIRM)

The Column Group

Alexsis de Raadt-St. James

Ironfire Ventures

UCB Ventures

Alexandria Venture Investments

Sphera Funds Management

Director of Discovery Research at Neurona, Marina Bershteyn, Ph.D., has been invited to present a seminar titled "Development of allogeneic GABAergic inhibitory interneuron cell therapy for drug-resistant focal epilepsy" at the Cell Based Therapeutics of Brain Diseases Meeting, which is part of the Neuroscience School of Advanced Studies Challenge Workshops. Marina's presentation will outline recent clinical data and supporting preclinical data from Neurona's ongoing clinical trial of NRTX-1001 which is demonstrating the potential to significantly reduce seizure frequency in adults with unilateral mesial temporal lobe epilepsy (MTLE). 
Learn more about NRTX-1001 and our clinical trials here: https://lnkd.in/e37V9uf2
Learn more about the meeting here: https://lnkd.in/eVRp7Wbx

We are delighted to announce that Manher (AJ) Joshi, M.D., has joined Neurona as Chief Medical Officer. AJ brings a wealth of clinical development and commercialization expertise across a variety of neuro-focused indications and has extensive experience in the development of cell therapies. We look forward to his leadership as we advance our pipeline of cellular therapeutic candidates for neurological diseases, including NRTX-1001 for drug-resistant focal epilepsy. Welcome to the Neurona team, AJ!
Learn more about AJ's background here: https://lnkd.in/eMjD7Tvs
#epilepsy #celltherapy

If you are attending the Jefferies Global Healthcare Conference in New York City this week, our CEO, Cory R. Nicholas, PhD, will be hosting meetings to update investors on the most recent data from Neurona's ongoing open-label Phase 1/2 clinical trial of NRTX-1001 in adults with drug-resistant, unilateral mesial temporal lobe epilepsy (MTLE) and the Company's plans to develop its pipeline of allogeneic, off-the-shelf, regenerative neural cell therapy products.
#epilepsy #celltherapy

If you are attending #ASGCT2024 please stop by Poster # 842 on Wednesday, May 8th when Neurona team member Brianna Feld will be presenting supporting preclinical data and the most recent clinical update from our hpsc-derived inhibitory interneuron cell therapy, NRTX-1001, which is being evaluated in an ongoing clinical trial in adults with drug-resistant focal #epilepsy.

At the Annual Meeting of the American Academy of Neurology ,#AAN2024, today, our CEO, Cory R. Nicholas, PhD, is presenting a clinical update on the first cohort of our ongoing Phase I/II clinical trial of NRTX-1001, which is being evaluated in people with drug-resistant focal #epilepsy. Read the details in our press release here: https://lnkd.in/e4yuHJiK

Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Google Tag Manager

HSTS

Google Analytics

Google Maps

Amazon

Global Site Tag

LetsEncrypt

Chief Technology Officer

Gautam Banik

Sr. Director, Head of People

Cecilia Machuca

Finance and Administration

James Tanaka

Engineering

Marina Bershteyn

Sr Director, Head of Regulatory

Paurene Duramad

Principal Scientist- Group Leader

Seonok Lee, Ph.D.

Operations

Dean Parent

Business Management

Margaret Cobos

Clinical Research & Development Manager

Rose Larios

Chief Medical Officer

Aj Joshi

Erica Whittaker

Arnold Kriegstein

James Stutz

Chief Financial Officer / Chief Business Officer

AJ Joshi

Nadia Agopyan

Senior Vice President of Regulatory Affairs

Cory R. Nicholas

Co-Founder & CEO

Tim Kutzkey

Co-Founder

Raymond J. Kelleher

Managing Director

San Francisco Bay Area Late Stage Companies With More Than 10 Employees

The Column Group Portfolio Companies

United States Companies With More Than 10 Employees (Top 10K)

United States Companies With Fewer Than 50 Employees (Top 10K)

Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeutic compositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.

Grant - Neurona Therapeutics

Cormorant Asset Management

Viking Global Investors

Series E - Neurona Therapeutics

Venture Round - Neurona Therapeutics

Series A - Neurona Therapeutics

San Francisco

California

United States

North America

Neumora Therapeutics to Participate in Upcoming Conferences in November

Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy

Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs

Neurona Therapeutics Receives FDA's Regenerative Medicine

Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer

Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference

A cell therapy for drug-resistant focal epilepsy, using human MGE-type inhibitory GABAergic interneurons derived from pluripotent stem cells, intended as a single, one-time dose.

A therapy using human oligodendrocyte cells derived from pluripotent stem cells, aimed at restoring myelin and repairing the nervous system in various disorders.

Cell therapies genetically modified for targeted delivery of therapeutic factors to the CNS, overcoming traditional drug delivery barriers.

news impact assignment basic	general
public peers	general	Jul 11, 2024 3:53 PM	f7d45d1b
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:09 AM	86a7616a
crunchbase profile	general	Nov 25, 2024 9:45 AM	3f9dfaef
li profile	general	Jul 11, 2024 3:53 PM	8646aa7a
translate crunchbase fundingrounds	general	Nov 25, 2024 1:50 PM	f1f60396
peers	general	Jul 11, 2024 3:53 PM	53c50586
news basic	general	Jul 11, 2024 3:53 PM	eebaaa3b
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:NEURONATHERAPEUTICS

Neurona Therapeutics